BeiGene, Ltd.

General Information
Business:

We are a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival. We further believe that discovery of next-generation cancer therapies requires new research tools. To that end, we have developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support our drug discovery effort.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 194
Founded: 2010
Contact Information
Address c/o Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands
Phone Number +1 (345) 949 4123
Web Address http://www.beigene.com
View Prospectus: BeiGene, Ltd.
Financial Information
Market Cap $756.4mil
Revenues $5.5 mil (last 12 months)
Net Income $-33.6 mil (last 12 months)
IPO Profile
Symbol BGNE
Exchange NASDAQ
Shares (millions): 6.6
Price range $24.00 - $24.00
Est. $ Volume $158.4 mil
Manager / Joint Managers Goldman Sachs/ Morgan Stanley/ Cowen and Company
CO-Managers Baird
Expected To Trade: 2/3/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change